Developing stem cell therapies: expansion strategies and lessons learned
Sponsor
The field of mesenchymal stem/stromal cell (MSC) therapy for critically ill patients has been evolving rapidly since the emergence of preclinical studies on the beneficial effect of MSCs in improving survival and organ functions of septic animal models. Results of a Phase 1, dose-escalation safety trial recently completed by Research scientists from Ottawa Hospital Research Institute (OHRI) suggest that MSCs are safe and well tolerated in patients with septic shock. The OHRI team is now pursuing a Phase II randomized controlled trial to continue the safety evaluation and look for signs of efficacy.
In this webinar, OHRI Investigator Dr. Shirley Mei and Senior Scientist Dr. Lauralyn McIntyre will discuss how their team translated a MSC therapy manufacturing process from the preclinical laboratory to a GMP setting, and what considerations were taken to design a first in human trial to examine MSCs for the treatment of septic shock. Corning Field Applications Scientist Dr. Catherine Siler will present tools and process design strategies for achieving consistent and efficient expansion of therapeutic cells, including scale-up and scale-out options and closed system designs.
- Challenges in developing a cell therapy product for acutely ill patients
- Trial design consideration for assessing safety of MSC therapy in septic shock
- Lessons learned from cell therapy products used in our early phase trial
- Process design for consistent and efficient scale up of therapeutic cells
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
